Over 90 Total Lots Up For Auction at One Location - WA 04/08

POINT Biopharma and Isotopia announce Lutetium-177 clinical supply agreement

Press releases may be edited for formatting or style | July 26, 2021 Molecular Imaging
INDIANAPOLIS, INDIANA and PETACH TIKVA, Israel, – POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to radiopharmaceuticals, and Isotopia Molecular Imaging Limited (Isotopia), a global supplier of radioisotopes for targeted therapies, today announced that they have signed a clinical supply agreement for the medical radioisotope no-carrier-added Lutetium-177 (n.c.a. Lu-177), a therapeutic isotope used in POINT’s pipeline of radiopharmaceutical assets.

Lu-177 is used in Precision Oncology for Targeted Radionuclide Therapy. The 6.6-day half-life of Lu-177 is sufficiently short for use with a variety of radiopharmaceuticals, and long enough to minimize decay loss during preparation and shipping of the radiopharmaceutical. Lu-177 damages tumors when bound to disease-specific targeting therapeutics, such as POINT’s PSMA targeting drug candidate PNT2002 for metastatic castration-resistant prostate cancer (mCRPC). Isotopia has developed a unique, stable, and reliable GMP method to produce a highly pure form of n.c.a. Lu-177. Isotopia’s Lu-177 contains no metastable Lu-177m, eliminating cost intensive clinical waste management. Isotopia’s Lu-177 will be used at POINT’s Indianapolis facility in the manufacturing of its therapeutic radioligand therapies.

“One of POINT’s key focuses has been building a robust and fault-redundant supply chain, as the materials sourcing, manufacturing and logistics hurdles in the radiopharmaceutical industry are significant.”, said Dr. Joe McCann, CEO of POINT. “As a leading supplier of high purity radioisotopes, Isotopia is an ideal partner for us; their ability to reliable delivery n.c.a Lu-177 will further strengthen our manufacturing facility’s ability to efficiently deliver finished clinical product for our ongoing clinical trials.”
stats
DOTmed text ad

Your Centrifuge Specialty Store

Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576

stats
Dr. Eli Shalom, CEO of Isotopia added, “As Isotopia expands its manufacturing capabilities to secure supply for patients worldwide, we are always looking to partner with leaders in the radiopharmaceutical space and provide dependable support at all stages, clinical and commercial. Given the highly professional leadership team and promising research to date, POINT Biopharma has positioned itself to deliver radiopharmaceutical therapies that improve the outcomes and lives of cancer patients. We are truly proud to be partnering with their company on this journey.”


About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.


About Isotopia
Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and some of Israel’s leading scientists in the field of radiopharmaceuticals and sterile manufacturing. The Isotopia development team is a multidisciplinary team consisting of professional Quality Assurance, Chemists, Microbiologists, Engineers Operations and Logistics. The experienced Isotopia team, together with its GMP certified plant – by the IL MOH and US FDA – and centralized radio-nuclear pharmacy, cyclotron facility, carrier free 177Lu production site, are a well-established platform for development. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications, molecular therapy and providing CMO services.

You Must Be Logged In To Post A Comment